Figure 2

In vivo response to ADPM-mediated PDT delivered with short drug–light interval. (A) Photographs of LLC/1 syngeneic murine tumour model before, 48 and 96 h after treatment (2 mg kg⁻¹ ADPM06+150 J cm⁻² light). (B) and (C) MDA-MB-231-GFP xenograft tumour ablation after treatment (2 mg kg⁻¹ ADPM06+150 J cm⁻² light) as shown by reduction in measurable tumour fluorescence. Representative images of a single animal from four repeat studies. Decreasing fluorescence intensity values are shown (photons per second per cm² per steradian). (D) ADPM06 efficacy study in MDA-MB-231-GFP xenograft model. Treatment groups were as follows: PDT group (2 mg kg⁻¹ ADPM06 IV+150 J cm⁻² light (n=7)), light-alone group (150 J cm⁻² (n=8)), drug-alone group (2 mg kg⁻¹ ADPM06 i.v. (n=14)), and vehicle control (n=9).